Methodology and technology for peripheral and central blood pressure and blood pressure variability measurement: current status and future directions - Position statement of the European Society of Hypertension Working Group on blood pressure monitoring and cardiovascular variability.

PubWeight™: 0.77^‹?›

🔗 View Article (PMID 27214089)

Published in J Hypertens on September 01, 2016

Author Affiliations

1: aHypertension Center STRIDE-7, National and Kapodistrian University of Athens, Third Department of Medicine, Sotiria Hospital, Athens, Greece bDepartment of Medicine and Surgery, University of Milan-Bicocca cDepartment of Cardiovascular Neural and Metabolic Sciences, S.Luca Hospital, IRCCS Istituto Auxologico Italiano, Milan, Italy dFirst Department of Cardiology, Hippokration Hospital, Medical School, National and Kapodistrian University of Athens eFourth Department of Medicine, Evangelismos General Hospital, Athens, Greece fFoundation-Medical Research Institutes (F-MRI), France gDepartment of Biomedical Sciences, Faculty of Medicine and Health Sciences, Macquarie University, Sydney, Australia hGeriatric Department University Hospital of Nancy, FHU CARTAGE and INSERM U1116 Université de Lorraine, France iUniversité Paris Descartes, Hôpital Européen Georges Pompidou, Assistance Publique Hôpitaux de Paris, France jIRCCS Fondazione Don Carlo Gnocchi, Milan, Italy kDepartment of Medicine, University of Barcelona & Hypertension Unit, Hospital Mutua Terrassa, Spain lStroke and Hypertension Unit, Connolly Hospital, Dublin, Ireland mBaker IDI Heart and Diabetes Institute, Melbourne, Victoria, Australia nDepartment of Planning for Drug Development and Clinical Evaluation, Tohoku University Graduate School of Pharmaceutical Sciences, Japan oDivision of Cardiovascular Medicine, Jichi Medical University School of Medicine, Shimotsuke, Japan pHypertension Center, 3rd Department of Medicine, Papageorgiou Hospital, Aristotle University of Thessaloniki, Greece qDepartment of Clinical Therapeutics, National and Kapodistrian University of Athens, Alexandra Hospital, Greece rNuffield Department of Primary Care Health Sciences, University of Oxford, UK sESH Excellence Centre, Kerckhoff Clinic Bad, Nauheim, Germany tNorthern Sydney Local Health District & University of Sydney, Australia uDivision of Cardiology, Sunnybrook Health Sciences Centre, Toronto, Canada vDepartment of Heal

Articles citing this ↘

Central Systolic Hypertension in Patients with Well-Controlled Hypertension. Biomed Res Int (2017) 0.75

Articles by these authors ⇆

Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med (2008) 38.76

2007 Guidelines for the Management of Arterial Hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens (2007) 20.09

2013 ESH/ESC Guidelines for the management of arterial hypertension: the Task Force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens (2013) 18.17

Expert consensus document on arterial stiffness: methodological issues and clinical applications. Eur Heart J (2006) 17.53

Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial--Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial. Lancet (2003) 17.34

Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials. Lancet (2009) 13.64

Genetic variants in novel pathways influence blood pressure and cardiovascular disease risk. Nature (2011) 13.25

Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trial. Lancet (2005) 12.92

2013 ESH/ESC guidelines for the management of arterial hypertension: the Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Eur Heart J (2013) 12.73

Point: cardiovascular variability is/is not an index of autonomic control of circulation. J Appl Physiol (1985) (2006) 11.52

Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial. Lancet (2004) 11.13

Rapid blood-pressure lowering in patients with acute intracerebral hemorrhage. N Engl J Med (2013) 11.10

2007 Guidelines for the management of arterial hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Eur Heart J (2007) 9.43

European guidelines on cardiovascular disease prevention in clinical practice. Third Joint Task Force of European and Other Societies on Cardiovascular Disease Prevention in Clinical Practice. Eur Heart J (2003) 8.51

Prognostic significance of visit-to-visit variability, maximum systolic blood pressure, and episodic hypertension. Lancet (2010) 8.39

Arterial stiffness and risk of coronary heart disease and stroke: the Rotterdam Study. Circulation (2006) 8.18

Global, regional, and national comparative risk assessment of 79 behavioural, environmental and occupational, and metabolic risks or clusters of risks in 188 countries, 1990-2013: a systematic analysis for the Global Burden of Disease Study 2013. Lancet (2015) 7.99

Global, regional, and national disability-adjusted life years (DALYs) for 306 diseases and injuries and healthy life expectancy (HALE) for 188 countries, 1990-2013: quantifying the epidemiological transition. Lancet (2015) 6.13

European guidelines on cardiovascular disease prevention in clinical practice: full text. Fourth Joint Task Force of the European Society of Cardiology and other societies on cardiovascular disease prevention in clinical practice (constituted by representatives of nine societies and by invited experts). Eur J Cardiovasc Prev Rehabil (2007) 6.10

Aortic stiffness is an independent predictor of primary coronary events in hypertensive patients: a longitudinal study. Hypertension (2002) 6.06

European Society of Hypertension recommendations for conventional, ambulatory and home blood pressure measurement. J Hypertens (2003) 5.94

Short-term effects of daily aspirin on cancer incidence, mortality, and non-vascular death: analysis of the time course of risks and benefits in 51 randomised controlled trials. Lancet (2012) 5.81

Increase in nocturnal blood pressure and progression to microalbuminuria in type 1 diabetes. N Engl J Med (2002) 5.72

A calcium antagonist vs a non-calcium antagonist hypertension treatment strategy for patients with coronary artery disease. The International Verapamil-Trandolapril Study (INVEST): a randomized controlled trial. JAMA (2003) 5.67

The Japanese Society of Hypertension Guidelines for the Management of Hypertension (JSH 2009). Hypertens Res (2009) 5.24

ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD: the Task Force on diabetes, pre-diabetes, and cardiovascular diseases of the European Society of Cardiology (ESC) and developed in collaboration with the European Association for the Study of Diabetes (EASD). Eur Heart J (2013) 5.23

Prognostic accuracy of day versus night ambulatory blood pressure: a cohort study. Lancet (2007) 5.21

Dogma disputed: can aggressively lowering blood pressure in hypertensive patients with coronary artery disease be dangerous? Ann Intern Med (2006) 5.18

Superiority of ambulatory over clinic blood pressure measurement in predicting mortality: the Dublin outcome study. Hypertension (2005) 5.05

The Study on Cognition and Prognosis in the Elderly (SCOPE): principal results of a randomized double-blind intervention trial. J Hypertens (2003) 4.91

Reappraisal of European guidelines on hypertension management: a European Society of Hypertension Task Force document. J Hypertens (2009) 4.87

The Japanese Society of Hypertension Guidelines for the Management of Hypertension (JSH 2014). Hypertens Res (2014) 4.83

Associations of kidney disease measures with mortality and end-stage renal disease in individuals with and without hypertension: a meta-analysis. Lancet (2012) 4.75

Prognostic value of ambulatory and home blood pressures compared with office blood pressure in the general population: follow-up results from the Pressioni Arteriose Monitorate e Loro Associazioni (PAMELA) study. Circulation (2005) 4.69

Prognostic significance of the nocturnal decline in blood pressure in individuals with and without high 24-h blood pressure: the Ohasama study. J Hypertens (2002) 4.63

2007 ESH-ESC Practice Guidelines for the Management of Arterial Hypertension: ESH-ESC Task Force on the Management of Arterial Hypertension. J Hypertens (2007) 4.59

Prognostic value of ambulatory blood-pressure recordings in patients with treated hypertension. N Engl J Med (2003) 4.59

Albuminuria and kidney function independently predict cardiovascular and renal outcomes in diabetes. J Am Soc Nephrol (2009) 4.43

Effectiveness of blood pressure control outside the medical setting. Hypertension (2006) 4.38

European Society of Hypertension position paper on ambulatory blood pressure monitoring. J Hypertens (2013) 4.28

Aortic stiffness is an independent predictor of fatal stroke in essential hypertension. Stroke (2003) 4.10

Working Group on Blood Pressure Monitoring of the European Society of Hypertension International Protocol for validation of blood pressure measuring devices in adults. Blood Press Monit (2002) 4.02

Effects of beta blockers and calcium-channel blockers on within-individual variability in blood pressure and risk of stroke. Lancet Neurol (2010) 3.93

Prevalence and factors associated with circadian blood pressure patterns in hypertensive patients. Hypertension (2009) 3.93

Expert consensus document on the measurement of aortic stiffness in daily practice using carotid-femoral pulse wave velocity. J Hypertens (2012) 3.73

Principal results of the Controlled Onset Verapamil Investigation of Cardiovascular End Points (CONVINCE) trial. JAMA (2003) 3.71

Effects of intensive blood pressure reduction on myocardial infarction and stroke in diabetes: a meta-analysis in 73,913 patients. J Hypertens (2011) 3.50